Evidence map›Paper›PMID 34885141›Full record

ArticleCancers2021

Evaluation of 3-l- and 3-d-[

Felicia Krämer, Benedikt Gröner, Chris Hoffmann, Austin Craig, Melanie Brugger, Alexander Drzezga, Marco Timmer, Felix Neumaier, Boris D Zlatopolskiy, Heike Endepols and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Radiosynthesis and Preclinical Evaluation ofMolecular pharmaceutics · 2024
    Article
  3. Next Generation Copper Mediators for the Efficient Production ofChemistry (Weinheim an der Bergstrasse, Germany) · 2023
    Article
  4. Recent Advances inPharmaceutics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Felicia KrämerInstitute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Benedikt GrönerInstitute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0002-2355-3017
Chris HoffmannInstitute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0003-1093-0183
Austin CraigInstitute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Melanie BruggerNuclear Chemistry (INM-5), Institute of Neuroscience and Medicine, Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428 Jülich, Germany.
Alexander DrzezgaDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Marco TimmerCenter for Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Felix NeumaierInstitute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0002-6376-6391
Boris D ZlatopolskiyInstitute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0001-5818-1260
Heike EndepolsInstitute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0002-6166-4818
Bernd NeumaierInstitute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0001-5425-3116
Forschungszentrum Jülich · DEUniversity of Cologne · DE

Funding

Deutsche Forschungsgemeinschaft EN 439/6-1Deutsche Forschungsgemeinschaft ZL 65/1-1Deutsche Forschungsgemeinschaft ZL 65/3-1
6 · The paper itself

Abstract

purposeThe preclinical evaluation of 3-l- and 3-d-[

methodsIn vitro studies were conducted with MCF-7, PC-3, and U87 MG human tumor cell lines. In vivo µPET studies were conducted in healthy rats with/without the inhibition of peripheral aromatic l-amino acid decarboxylase by benserazide pretreatment (

resultsThe uptake of 3-l-[

conclusionBoth novel tracers enable accurate tumor delineation with an imaging quality comparable to [

Indexed as

[18F]FPheglioblastomanuclear medicineorthotopic xenograft modelPETradiotracer

Identifiers

PMID34885141
PMCPMC8656747
OpenAlexW3215336940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.